Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has reported detailed data from the third phase BOSTON study that the company will present at this year’s American Society of Oncology (ASCO) Virtual Scientific Program to be held on May 29, 2020.
BOSTON study showed 47% median PFS in patients
The BOSTON study evaluated the combination of XPOVIO (selinexor) and Velcade (bortezomib) once per week with 40mg low dose dexamethasone weekly relative to the standard twice per week Velcade and 80mg low dose dexamethasone per week in multiple myeloma patients that had received between one and three previous lines of therapy. The company previously reported that the BOSTON study achieved its primary endpoint, demonstrating a substantial increase in the average progression-free survival in multiple myeloma patients after one to three previous therapy lines.
Meletios Dimopoulos, who is the chairman of National and Kapodistrian University of Athens School of Medicine’s Clinical Therapeutics Department, was the lead investigator in the BOSTON study. Dimopoulos indicated that in the clinical data that is to be presented at this year’s ASCO, the once per week SVd showed a significant increase in median progression-free survival at 47% relative to the standard twice per week Vd regimen.
XPOVIO combination with Velcade to help the treatment of multiple myeloma
Similarly, it demonstrated consistent benefit across several important patient cohorts like those that had been treated previously with lenalidomide as well as those having high-risk cytogenetics. Equally, the lead investigator pointed out that the clinically important benefits shown in the study indicate that once approved in the expanded patient groups, XPOVIO will be a convenient and vital addition in the treatment sphere.
The company has already submitted a supplemental New Drug Application with the FDA seeking approval for using XPOVIO with Velcade as well as low dose dexamethasone as a novel treatment for multiple myeloma patients that have been treated previously. Also, there are plans to file for Market Authorization Application to EMA seeking approval for the same indication in Europe later this year.
